U.S. Markets closed

Wired News – Kadmon Presented Updated Positive Results from Phase-2 Study of KD025 in Chronic Graft-Versus-Host Disease at BMT Tandem Meetings

Stock Monitor: Vanda Pharma Post Earnings Reporting

LONDON, UK / ACCESSWIRE / February 26, 2018 / Active-Investors.com has just released a free research report on Kadmon Holdings, Inc. (NYSE: KDMN). If you want access to this report all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=KDMN as the Company's latest news hit the wire. On February 22, 2018, the Company announced on updated results from an ongoing Phase-2 clinical trial (KD025-208) evaluating KD025 in patients with chronic graft-versus-host disease (cGVHD), a serious complication following allogeneic bone marrow or stem cell transplantation. The results were presented at the BMT Tandem Meetings in Salt Lake City. Register today and get access to over 1,000 Free Research Reports by joining our site below:

www.active-investors.com/registration-sg

Active-Investors.com is currently working on the research report for Vanda Pharmaceuticals Inc. (NASDAQ: VNDA), which also belongs to the Healthcare sector as the Company Kadmon Holdings. Do not miss out and become a member today for free to access this upcoming report at:

www.active-investors.com/registration-sg/?symbol=VNDA

Active-Investors.com is focused on giving you timely information and the inside line on companies that matter to you. This morning, Kadmon Holdings most recent news is on our radar and our team decided to put out a fantastic report on the company that is now available for free below:

www.active-investors.com/registration-sg/?symbol=KDMN

Updated Results in cGVHD

  • Updated data from Cohort 2 of KD025-208 conducted in adults with steroid-dependent or steroid-refractory cGVHD and active disease (200 mg BID; n=16) showed an Overall Response Rate (ORR) of 69%, as of a data cutoff date of January 03, 2018.
  • The ORR in Cohort 1 (n=17) remained 65%. Responses were rapid, with approximately 70% of patients across Cohorts 1 and 2 achieving responses by the first assessment after 8 weeks of treatment.
  • Responses were observed across all affected organs, including in organs with fibrotic manifestations of the disease. In responders with four or more organs involved, 46% showed responses in at least four organs. 64% of patients were able to reduce steroid dose, and four patients completely discontinued steroid use.
  • 83% of patients were able to reduce the dose of tacrolimus, another immunosuppressive agent used to treat cGVHD. KD025 was well tolerated, with no drug-related serious adverse events in either cohort were observed.
  • Kadmon expects to enroll an expansion cohort of approximately 40 patients after the optimal dose has been determined.

Kadmon Reported Positive Data from Phase-2 Study of KD025 in Idiopathic Pulmonary Fibrosis

On February 12, 2018, the Company also announced topline results from an ongoing Phase-2 clinical trial evaluating KD025 in patients with idiopathic pulmonary fibrosis (IPF) who were previously treated with or offered pirfenidone and/or nintedanib. KD025 was well tolerated and demonstrated clinical benefit, with a median decline in forced vital capacity, a measure of lung function, of 48 mL at week 24, compared to a median decline of 175 mL in patients treated with best supportive care, an absolute difference of 127 mL, and a relative difference of 73%.

FDA Approved Drug for Treatment of cGVHD

In August 2017, the FDA approved IMBRUVICA® (ibrutinib) for the treatment of adult patients with cGVHD after failure of one or more lines of systemic therapy. IMBRUVICA is the first and only FDA-approved medication for adult patients with cGVHD. IMBRUVICA is a first-in-class Bruton's tyrosine kinase (BTK) inhibitor jointly developed and commercialized by Janssen Biotech, Inc., and Pharmacyclics LLC, an AbbVie company. The approval was based on results from an open-label, multi-center, single-arm Phase-1b/2 trial (PCYC-1129) evaluating the safety and efficacy of ibrutinib in 42 patients with cGVHD who failed first-line corticosteroid therapy and required additional therapy.

About Chronic Graft-Versus-Host Disease (cGVHD)

GvHD is a condition that might occur after an allogeneic transplant. In GvHD, the donated bone marrow or peripheral blood stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body, leading to inflammation and fibrosis in multiple tissues, including skin, mouth, eye, joints, liver, lung, esophagus, and GI tract.

About KD025

KD025 is an oral small molecule inhibitor of the Rho-associated coiled-coil kinase (ROCK) signaling pathway and the lead candidate in our ROCK inhibitor platform. In October 2017, the US Food and Drug Administration (FDA) granted orphan drug designation to KD025 for the treatment of cGVHD.

About Kadmon Holdings, Inc.

Founded in 2009 and headquartered in New York City, New York, Kadmon is a fully integrated biopharmaceutical company engaged in the discovery, development, and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The Company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases.

Stock Performance Snapshot

February 23, 2018 - At Friday's closing bell, Kadmon Holdings' stock advanced 1.11%, ending the trading session at $3.64.

Volume traded for the day: 989.33 thousand shares, which was above the 3-month average volume of 926.35 thousand shares.

Stock performance in the last three-month – up 1.39%; previous six-month period – up 57.58%; and year-to-date - up 0.55%

After last Friday's close, Kadmon Holdings' market cap was at $283.08 million.

The stock is part of the Healthcare sector, categorized under the Biotechnology industry. This sector was up 1.4% at the end of the session.

Active-Investors:

Active-Investors (A-I) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. A-I has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

A-I has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@active-investors.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by A-I. A-I is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

A-I, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. A-I, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, A-I, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither A-I nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://active-investors.com/legal-disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@active-investors.com

Phone number: 73 29 92 6381

Office Address: 6, Jalan Kia Peng, Kuala Lumpur, 50450 Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Active-Investors